AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Recordati Industria Chimica e Farmaceutica

Declaration of Voting Results & Voting Rights Announcements May 3, 2022

4056_rns_2022-05-03_e7004ea0-ba03-4a99-bdad-d96a6607409a.pdf

Declaration of Voting Results & Voting Rights Announcements

Open in Viewer

Opens in native device viewer

RECORDATI: SUMMARY REPORT OF THE VOTES - ORDINARY GENERAL MEETING OF THE SHAREHOLDERS 29.04.2022

Milan, 3rd May 2022 – Please be informed that the summary report of the voting results related to the resolutions approved by the Ordinary General Meeting of the Shareholders on 29th April 2022, pursuant to article 125-quater of the Legislative Decree 58/98, is available to the public on the Company's website (www.recordati.it, in the area "Investors", section "Shareholders' Meetings") and on the storage mechanism ().

Recordati (Reuters RECI.MI, Bloomberg REC IM), established in 1926, is an international pharmaceutical group listed on the Italian Stock Exchange (ISIN IT 0003828271), with a total staff of more than 4,300, dedicated to the research, development, manufacturing and marketing of pharmaceuticals. Headquartered in Milan, Italy, Recordati has operations in Europe, Russia and other countries of the CIS, Ukraine, Turkey, North Africa, the United States, Canada, Mexico, some South American countries, Japan and Australia. An efficient field force of medical representatives promotes a wide range of innovative pharmaceuticals, both proprietary and under licence, from a number of therapeutic areas, including a specialised business dedicated to rare diseases. Recordati is a partner of choice for new product licences for its territories. Recordati is committed to the research and development of new specialties with a focus on treatments for rare diseases. Consolidated revenue for 2021 was €1,580.1 million, operating income was €490.2 million and net income was €386.0 million.

Further information:

Recordati website: www.recordati.it

Investor Relations Investor Relations Press Office (39) 02 48787146 (39) 02 48787213 (39) 02 9288 6200

Federica De Medici Lucia Abbatantuoni Brunswick: Barbara Scalchi / Andrea Mormandi email: [email protected] e-mail: [email protected] e-mail: [email protected]

RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.p.A.

Registered office VIA M. CIVITALI, 1 20148 MILAN, ITALY TEL. +39 0248787.1 FAX +39 0240073747 SHARE CAPITAL € 26,140,644.50 fully paid up BUSINESS REGISTER OF MILAN, MONZA, BRIANZA and LODI 00748210150 TAX CODE/VAT NO. 00748210150

Company subject to management and coordination by Rossini Luxembourg S.àr.l MILAN ECONOMIC AND ADMINISTRATIVE INDEX (REA) 401832

Talk to a Data Expert

Have a question? We'll get back to you promptly.